FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-02										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Goldberg Andrew D.					2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [ TARS ]								(Ch	neck all applic	or		10% Ow	ner	
	RSUS PHAI	RMACEUTICA		0		3. Date of Earliest Transaction (Month/Day/Year) 06/15/2021									Officer (give title below)		Other (sp below)	pecify	
15440 LAGUNA CANYON ROAD, SUITE 160						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) IRVINE	C	A	92618										X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,			3. Transaction Code (Instr. r) 8) 4. Securities Acquir Disposed Of (D) (Instr. 5)			Beneficia Owned F	es ally following	Form: Direct (D) or Indirect (I) (Instr. 4)	Direct of Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code V	Amo	unt	(A) or (D)	Price	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)		
		-	Γable II - D (€						uired, Dis , options,					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Day if any (Month/Day/	Co	Transaction Code (Instr.				6. Date Exerc Expiration D (Month/Day/	ate	nd	7. Title and of Securiti Underlying Derivative (Instr. 3 and	es J Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owr Forr Dire or Ir (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode \	v	(A)	(D)	Date Exercisable	Expirati Date	on	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$35.26	06/15/2021		,	A		7,500		(1)	06/15/20	031	Common Stock	7,500	\$0.00	7,500		D		
Stock Option (right to buy)	\$35.26	06/15/2021			A		10,000		(2)	06/15/20	031	Common Stock	10,000	\$0.00	10,000		D		

## Explanation of Responses:

- 1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
- 2. Option granted in connection with the Reporting Person's service as a non-employee director as of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

## Remarks:

/s/ Leo Greenstein

06/17/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.